AbbVie's Skyrizi (risankizumab) Receives European Commission's Approval for Moderate to Severe Plaque Psoriasis
Shots:
- The EC approval is based on four P-III ultIMMa-1- ultIMMa-2- IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO- adalimumab- ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis
- The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%- 84% & 75%); Skyrizi vs adalimumab- PASI 90 (72% vs 47%); switched patients vs continued adalimumab- PASI 90 (66% vs 21%); @16wks. & 52wks. met its co-1EPs; Skyrizi vs ustekinumab- (DLQI) score (75% & 71% vs 47% & 44%)
- Skyrizi (risankizumab) is a humanized immunoglobulin mAb- inhibits IL-23 by binding to its p19 subunit and has received MHLW’s approval for multiple plaque psoriasis conditions in Mar’19 & Health Canada and the US FDA approval for moderate to severe plaque psoriasis in Apr’19
Ref: AbbVie | Image:AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com